Gemcitabine and Gem Combination / Mesothelioma

Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F. Department of Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.
Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME. Department of Pneumonology, Medical School Democritus University of Thrace, Alexandroupolis, Greece.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Dana Farber Cancer Institute, Lowe Center for Thoracic Oncology, 44 Binney St, Dana D820A, Boston, MA 02115, USA. pjanne@partners.org

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A. Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy. paolo.zucali@humanitas.it

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM Jr, Soori GS, Nikcevich DA, Kardinal CG, Northfelt DW, Adjei AA; North Central Cancer Treatment Group.Collaborators (14) Wos E, Windschitl HE, Tschetter LK, Bernath A, Stella PJ, Dakhil SR, Kugler JW, Wender DB, Schaefer PL, Schwarzenberger P, Wiesenfeld M, Morton RF, Bearden JD 3rd, Jaslowski AJ.Department of Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. okuno.scott@mayo.edu

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC. Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. kalmads@ccf.org

Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF, Egorin MJ, Rubin EH, Poplin EA. The Cancer Institute of New Jersey, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey 08903, USA.

[The use of gemcitabine in the treatment of patients with mesothelioma]
Korman DB, Boronovskaia LE, Maslova IA. PMID: 17024824 [PubMed - indexed for MEDLINE]

Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
Utkan G, Büyükçelik A, Yalçin B, Akbulut H, Demirkazik A, Dinçol D, Onur H, Gören D, Mousa U, Senler FC, Içli F. Department of Medical Oncology, Ankara University School of Medicine, 06590-TR, Dikimevi, Ankara, Turkey.

Clinical studies of pemetrexed and gemcitabine combinations.
Adjei AA. Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA. adjei.alex@mayo.edu

Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
Maruyama R, Shoji F, Okamoto T, Miyamoto T, Miyake T, Nakamura T, Ikeda J, Aoki Y, Wataya H, Asoh H, Ichinose Y. Department of Thoracic Oncology, Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka 811-1395, Japan. rmaruyama@nk-cc.go.jp

Cisplatin and gemcitabine in malignant mesothelioma.
Nowak AK, Byrne MJ. PMID: 16000339 [PubMed - indexed for MEDLINE]

Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
Castagneto B, Zai S, Dongiovanni D, Muzio A, Bretti S, Numico G, Botta M, Sinaccio G. Department of Oncology, S. Spirito Hospital, Casale Monferrato (AL), Italy. bruno.castagneto@mbox.asl21.piemonte.it

Epirubicin and gemcitabine as first-line treatment in malignant pleural mesothelioma.
Portalone L, Antilli A, Nunziati F, Crispino C, DeMarinis F, Friggeri L, Lombardi A, Lorusso V, Pronzato P, Sambiasi D, Signora M; Associazione Italiana Pneumologi Ospedalieri Thoracic Oncology Study Group. 16th Pneumo-Oncology Unit, C. Forlanini Hospital, Rome, Italy. lportalone@virgilio.it

Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.
Aversa SM, Favaretto AG. Medical Oncology Department, Azienda Ospedaliera di Padova, Via Giustiniani, 2 35218 Padova Italy. jhqa-018@mailbox.dsnet.it

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
Schutte W, Blankenburg T, Lauerwald K, Schreiber J, Bork I, Wollscgkaeger B, Treutler D, Schneider CP, Bonner R. Second Medical Department, City hospital Martha-Maria Halle-Doelau, Halle, Germany. wolfgang.schuette@medizin.uni-halle.de

Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, Stefani M, Rea F, Bortolotti L, Loreggian L, Monfardini S. Department of Medical Oncology, University Hospital, Padova, Italy. agfavaretto@yahoo.it

Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study.
Xanthopoulos A, Bauer TT, Blum TG, Kollmeier J, Schönfeld N, Serke M. Respiratory Diseases Clinic Heckeshorn, Department of Pneumology, HELIOS Klinikum Emil von Behring, Berlin, Germany. torsten.bauer@helios-kliniken.de.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H. Dana Farber Cancer Institute, Lowe Center for Thoracic Oncology, 44 Binney St, Dana D820A, Boston, MA 02115, USA. pjanne@partners.org


Believe in a Cure!

Contact us here for immediate expert help and a free copy of the book "100 Questions & Answers About Mesothelioma."

(877) END-MESO
(877) 363-6376